An Overview of the BR-002 Trial in Breast Cancer

Julia White, MD
Published Online: March 27, 2014
Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the BR-002 trial, which will evaluate the rate of complete tumor ablation of breast cancers that are less than or equal to 2 centimeters.

Clinical Pearls:
  • This trial seeks to confirm that a local intervention does not change the outcome of a patient
  • Participants of the trial will be randomized to ablation or standard treatment
  • Women are only qualified for the trial if they are responding to chemotherapy or are in their first line of chemotherapy​


Related Articles
The development of drug resistance in cancer cells presents a major obstacle to cancer treatments of all types, including small molecule inhibitors, monoclonal antibodies, and hormone therapy.
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses future treatment options for triple-negative breast cancer (TNBC).
Recent data indicate a role for a pathway involved in controlling cell proliferation as a potential site for therapeutic intervention in breast cancer.
New research has identified a genetic variant that helps reduce the risk of breast cancer in some Latina patients by 40% to 80%.
JTT Articles
A Long-Awaited Treatment Option for Radioiodine- Refractory DTC
NCCN Guidelines Include Obinutuzumab in CLL
CD19-Targeted Agents Continue to Show Positive Outcomes
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.